Enveric Biosciences, INC DEF 14A proxy statements

Enveric Biosciences announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, a reverse stock split, and an increase in authorized shares.

Enveric Biosciences, Inc. calls a special meeting to seek stockholder approval for a reverse stock split, an increase in authorized shares, and the issuance of shares related to a recent warrant inducement transaction.

Enveric Biosciences has filed a definitive proxy statement with the SEC.

Enveric Biosciences is asking stockholders to approve a conditional reverse stock split to address potential future bid price deficiencies and maintain its Nasdaq listing.

Enveric Biosciences is asking shareholders to approve a reverse stock split to increase its share price and maintain its listing on the Nasdaq Capital Market.

Enveric Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on May 28, 2024, to elect directors, vote on executive compensation, ratify the appointment of the independent auditor, and conduct an advisory vote on the frequency of future executive compensation votes.